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phase will likely not alter postischemic stunning, although 
other mechanisms of injury would be engaged. This 
explanation is consistent with the data presented in the 
study by Randhawa, Lasley, and Mentzer a and is consis- 
tent with other studies related to the cardioprotective 
mechanisms of adenosine. 
The optimal timing of adenosine administration may 
span all three windows of protection: before treatment, 
during the ischemic event, and during reperfusion. In 
cardiac surgery, these three windows of protection are 
open. First, adenosine can be given as a pretreatment 
before the operation. Second, adenosine may be included 
as an adjunct o either crystalloid or blood cardioplegia, 6 
in which case it is administered uring surgical "pro- 
tected" ischemia. Third, adenosine may be administered 
after aortic unclamping and reperfusion. Which "window" 
of administration is most optimal, what dose is optimal, 
which receptors and effector systems are targets of aden- 
osine, and in which compartment(s) protective ffects are 
exerted in the surgical setting are questions that will keep 
young basic scientists and physician-investigators at the 
bench for some time. 
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Reply to the Editor: 
We thank Drs. Vinten-Johansen and Hammon for their 
interest in our work entitled "Salutary Effects of Exoge- 
nous Adenosine Administration on In Vivo Myocardial 
Stunning. ''1 We reported that adenosine's cardioprotec- 
tive effects were related to the preischemic elevation of 
adenosine in interstitial fluid and subsequent activation of 
adenosine A1 receptors located on the cardiac myocytes. 
We also concluded that denosine must be administered 
before ischemia to attenuate stunning, because postisch- 
emic infusion of adenosine only transiently improved 
systolic wall thickening. 
As pointed out by Vinten-Johansen and Hammon, in 
one protocol in this study we observed attenuation of 
stunning with an adenosine pretreatment dose (5 /xg/kg 
per minute) that did not elevate preischemic dialysate 
adenosine concentrations. Although we acknowledged 
that the cardioprotective effect of this dose could have 
occurred independent of increased interstitial f uid aden- 
osine, we concluded that the lack of increase in dialysate 
adenosine may have been due to the limitations of the 
dialysis technique. This technique provides only an esti- 
mate of interstitial f uid metabolites and is dependent on 
blood flow. In subsequent s udies in the pig (unpublished 
data) we observed that the same intracoronary adenosine 
infusion (5/xg/kg per minute) increased coronary venous 
adenosine fivefold (from 0.31 + 0.09 /zmol/L to 1.51 + 
0.32 p~mol/L). We detected a much smaller increase in 
dialysate adenosine--from 0.55 _ 0.05/xmol/L to 0.71 --- 
0.11 txmol/L. We thus agree with Van Wylen 2 that the 
threshold intracoronary adenosine dose for overcoming 
the coronary endothelial barrier is approximately 5/xg/kg 
per minute. 
Because both doses of adenosine undoubtedly in- 
creased plasma adenosine levels, adenosine A2 receptors 
were presumably activated. However, it is unlikely that the 
cardioprotective effects of adenosine pretreatment are 
related to preischemic activation of adenosine Ae recep- 
tors. This hypothesis i based on the results of numerous 
studies in which adenosine A 1 and A2 receptor agonists 
and adenosine receptor antagonists were used. The pre- 
ischemic activation of adenosine A 1 receptors appears to 
be critical for the cardioprotective effects of adenosine 
against both reversible and irreversible injury. In our 
recent study in a model of irreversible injury, we 3 ob- 
served that a transient intravenous adenosine infusion 
(i.e., adenosine preconditioning) briefly increased preisch- 
emic levels of myocardial dialysate adenosine and reduced 
infarct size. The adenosine preconditioning did not, how- 
ever, alter dialysate concentrations during the prolonged 
occlusion. These results are consistent with our working 
hypothesis that the cardioprotective effects of adenosine 
pretreatment are mediated by the preischemic activation 
of adenosine A1 receptors, irrespective of ischemic inter- 
stitial fluid adenosine levels. 
Although the cardioprotective effects of adenosine pre- 
treatment in models of stunning and infarction are 
thought o be mediated by adenosine Aa receptor activa- 
tion, we agree with Drs. Vinten-Johansen and Hammon 
that adenosine exerts beneficial effects during reperfusion 
of the irreversibly injured heart. As suggested by several 
studies from Dr. Vinten-Johansen's laboratory, these ef- 
fects appear to be mediated by activation of adenosine A 2 
receptors located on endothelial cells and neutrophils. In 
fact, there is evidence that, in contrast o the beneficial 
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effects of Az receptor activation, adenosine A 1 receptor 
activation during reperfusion may exacerbate r perfusion 
injury by promoting neutrophil adherence to endotheli- 
urn. 4 
The aforementioned studies emphasize the importance 
of the timing of adenosine treatment. There also remains 
one unexplained ifference between adenosine pretreat- 
ment effects on reversible and irreversible injury. A tran- 
sient adenosine infusion (adenosine preconditioning) that 
is terminated before the onset of ischemia can reduce 
infarct size 3 but does not attenuate stunning. 5 Regard- 
less of the mechanisms of adenosine-mediated cardio- 
protection and the optimal timing of adenosine infu- 
sion, there is evidence that adenosine pretreatment and 
supplementation of blood cardioplegic solution with 
adenosine may be beneficial in the setting of cardiac 
operations in human beings. 6 Finally, we also agree 
with Vinten-Johansen and Hammon that additional 
experimental nd clinical studies are needed to deter- 
mine the mechanism(s) and optimal timing/dose of 
adenosine-mediated cardioprotection. 
Robert D. Lasley, PhD 
Robert M. Mentzer, Jr, MD 
Department of Surgery 
University of Wisconsin School of Medicine 
Room H4/383 Clinical Science Center 
600 Highland Ave. 
Madison, WI 53792 
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Perfusion pressure and coronary bypass 
To the Editor: 
From their prospective study of 248 patients undergo- 
ing first-time coronary bypass, Gold and associates 1 con- 
cluded that higher perfusion pressures during cardio- 
pulmonary bypass improved all outcomes of operation. 
The authors would have us believe that increasing mean 
perfusion pressure from 52 to 70 mm Hg (Table IIIa: 
mean pressure recorded at all flows) for 90 minutes of 
cardiopulmonary bypass reduced permanent cardiac 
complications, reduced neurologic complications, and 
eliminated two deaths (one from multisystem failure 
and one from lung cancer) at 6 months after the 
operations. The incidences of cardiac complications, 
neurologic omplications, and death in the high-pres- 
sure compared with the low-pressure groups were not 
significantly different at the conventionalp < 0.05 level. 
When these outcomes were selectively pooled, however 
(congestive heart failure, minor neurologic deficits, 
cognitive outcomes, and deterioration i quality of life 
were arbitrairily omitted), a significant difference in 
"overall" outcome of morbidity and mortality was 
claimed (p < 0.026). 
As a justification for pooling outcomes, the authors 
invoked a common mechanism, namely, that the low- 
pressure group was "below the autoregulatory limits of 
the coronary and cerebral circulations." Autoregulation of
the cerebral circulation provides constancy of cerebral 
blood flow through a wide range of perfusion pressures, 
including 52 mm Hg. No such pressure-related autoregu- 
latory phenomenon occurs in the coronary circulation. 
Furthermore, the coronary circulation was not perfused 
at all during half of the bypass period because the aorta 
was crossclamped, and o data on the prevalence of 
postbypass and postoperative hypotension or hyperten- 
sion were included, even though these events are not 
rare. To ascribe all, albeit not significant, differences in 
postoperative cardiac omplications for 6 postoperative 
months to 45 minutes of perfusion at 18 mm Hg higher 
pressure during partial aortic occlusion bypass is diffi- 
cult to accept. 
In a separate publication 2 1 year earlier these same 
authors reported studies of cerebral embolization by 
transcranial Doppler sonography in 20 patients undergo- 
ing coronary bypass who appear to be a subset of the 248 
patients in the present study. They reported that postop- 
erative neurocognitive d terioration after coronary bypass 
was directly related to the embolic load to the brain, which 
was greatest at unclamping an atherosclerotic aorta dur- 
ing the operation. One patient among the three with the 
highest embolic load had a stroke during the operation. 
The present study did not include data on cerebral 
embolic load or on grading of atheromatous plaque of the 
aorta. Because the nonsignificant difference in neurologic 
outcome between the high- and low-pressure groups was 
the largest contributor to the difference in "overall" 
outcome, differences in the presence of aortic atheroma- 
tous disease between the two groups could completely 
explain the observed differences in outcome, without 
invoking differences in perfusion pressure. As the authors 
themselves state, "Clear relationships between the sever- 
ity of aortic disease, the number of ES [embolic signals] at 
cross clamp removal and neuropsychological outcome 
must be demonstrated before modification of surgical 
techniques are indicated. ''2 This caveat would and should 
